Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.

Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS.

Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

PMID:
23708063
2.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Eur Urol. 2012 May;61(5):888-95. doi: 10.1016/j.eururo.2012.01.012. Epub 2012 Jan 18.

PMID:
22269604
3.

Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.

Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2012 Feb;187(2):418-23. doi: 10.1016/j.juro.2011.10.024. Epub 2011 Dec 15.

PMID:
22177164
4.

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Apr 1;118(7):1795-802. doi: 10.1002/cncr.26453. Epub 2011 Aug 25.

5.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Jan;185(1):30-5. doi: 10.1016/j.juro.2010.09.013. Epub 2010 Nov 12.

PMID:
21074210
6.

Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.

La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ.

Cancer. 2010 Oct 15;116(20):4696-702. doi: 10.1002/cncr.25279.

7.

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900. doi: 10.1158/1055-9965.EPI-08-0786. Epub 2009 Feb 24.

8.

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Clin Oncol. 2009 Feb 10;27(5):746-53. doi: 10.1200/JCO.2007.15.8345. Epub 2009 Jan 5.

PMID:
19124809
9.

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ.

Cancer. 2008 Nov 1;113(9):2457-63. doi: 10.1002/cncr.23851.

10.

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.

Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ.

J Urol. 2008 Jan;179(1):61-6. Epub 2007 Nov 13.

PMID:
17997430
11.

A novel resectoscope for transurethral resection of bladder tumors and the prostate.

Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS.

J Urol. 2007 Dec;178(6):2331-6; discussion 2336. Epub 2007 Oct 22.

PMID:
17936809
12.

Prognostic factors for renal cell carcinoma with tumor thrombus extension.

Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS.

J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195. Epub 2007 Aug 14.

PMID:
17698087
14.

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.

Clin Cancer Res. 2006 Jul 1;12(13):4018-26.

15.

Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA.

Pantuck AJ, Zomorodian N, Belldegrun AS.

Curr Urol Rep. 2006 Jan;7(1):7. No abstract available.

PMID:
16480662
16.

Monoclonal antibody (MAB) in patients with advanced cancer.

Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS.

Curr Urol Rep. 2003 Feb;4(1):11-2. No abstract available.

PMID:
12537933

Supplemental Content

Loading ...
Support Center